Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia
Protein Kinase CK2 (Casein Kinase 2 or CK2) is a constitutively active serine-threonine kinase overactive in human malignancies. Increased expression and activity of CK2 in Acute Myeloid Leukemia (AML) is associated with a poor outcome. CK2 promotes AML cell survival by impinging on multiple oncogen...
Main Authors: | Morgann Klink, Mohammad Atiqur Rahman, Chunhua Song, Pavan Kumar Dhanyamraju, Melanie Ehudin, Yali Ding, Sadie Steffens, Preeti Bhadauria, Soumya Iyer, Cesar Aliaga, Dhimant Desai, Suming Huang, David Claxton, Arati Sharma, Chandrika Gowda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/5/1127 |
Similar Items
-
CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
by: Jomnarong Lertsuwan, et al.
Published: (2018-08-01) -
The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
by: Hae Jung eChon, et al.
Published: (2015-03-01) -
Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
by: Anna Richter, et al.
Published: (2020-03-01) -
Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
by: Laura Ferrer-Font, et al.
Published: (2017-02-01) -
Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
by: Mauro Rosales, et al.
Published: (2021-02-01)